Hydro Review is the trusted voice connecting the global market with an unparalleled volume & distribution of market-related solutions, news & insights. Over the last 52-week period, shares are down 16.33%. Stock analysis for Concert Pharmaceuticals Inc (CNCE:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Message Board Total Posts: 11 Post-Market 0.11 (3.56%) Our innovative approach has already resulted in multiple drug candidates that are progressing in clinical development. Roger Tung . Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) stock price is $3.03 as of the last check on Tuesday, Apr 26. CNCE Stock Message Board for Investors. Overview At Concert Pharmaceuticals, we are pioneering the use of deuterium chemistry to discover and develop innovative new medicines that positively impact patient care and address important medical needs. In other Concert Pharmaceuticals news, CEO Roger D. Tung sold 13,480 shares of the firm's stock in a transaction that occurred on Tuesday, February 15th. Shares of Concert Pharmaceuticals stock traded down $0.06 on Friday, reaching $3.20. The latest closing stock price for Concert Pharmaceuticals as of March 14, 2022 is 2.73.. Shares of Concert Pharmaceuticals were trading at $3.42 as of May 03. The . Contact Email info@concertpharma.com. CNCE has a higher number of analysts covering the stock than 144.38% of all US stocks. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-2.31 Market Cap $108.36 M Shares Outstanding 34.95 M Public. Concert Pharmaceuticals is registered under the ticker NASDAQ:CNCE . Post-Market 0.11 (3.56%) Concert Pharmaceuticals Inc NASDAQ Updated Apr 28, 2022 8:35 PM. Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform ® (deuterated chemical entity platform). Concert Pharmaceuticals, Inc. Analyst Report: Pfizer Inc. Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). Overview. Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical . Concert Pharmaceuticals ( NASDAQ:CNCE - Get Rating) last posted its earnings results on Thursday, May 5th. Over the last 52-week period, shares are down 16.33%. The Concert Pharmaceuticals stock price gained 6.13% on the last trading day (Monday, 25th Apr 2022), rising from $3.10 to $3.29. Concert Pharmaceuticals is funded by 14 investors. The analyst firm set a price target for 9.00 expecting CNCE to rise to within 12 . 2019-02-07 sec.gov - Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 7, 2019 with respect to the common stock, par value $0.001 per share, of Concert Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of . Concert Pharmaceuticals Concert is developing innovative medicines with unique therapeutic properties to address the needs of patients with chronic diseases. The firm has a market cap of $118.43 million, a P/E ratio of -1.42 and a beta of 0.40. Last Funding Type Post-IPO Equity. Operating Status Active. CNCE stock opened at $3.26 on Friday. Concert Pharmaceuticals (CNCE) stock price, charts, trades & the US's most popular discussion forums. Concert Pharmaceuticals, Inc. Main Stock Listing show_chart NASDAQ: CNCE Market Capitalization History of Concert Pharmaceuticals, Inc. Market capitalizations are calculated from the opening stock price at the beginning of each month. The firm has a market cap of $118.43 million, a P/E ratio of -1.42 and a beta of 0.40. 5, 2022, 08:45 AM Concert Pharmaceuticals (CNCE) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.93. At Concert Pharmaceuticals, we are pioneering our industry-leading expertise in deuterium chemistry to discover and develop innovative drug products that have impact for patients and address important medical needs. Concert Pharmaceuticals, Inc. Stock Price, News and Company Updates. Sector Health Care Industry Biotechnology Employees 64 Founded 2006 Address 65 Hayden Avenue Suite 3000N. Why Concert Pharmaceuticals Stock Is Soaring Today. The management is top of the line, only worry would be a quick buyout. Shares of Concert Pharmaceuticals were trading at $3.42 as of May 03. CNCE, Concert Pharmaceuticals - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Best dividend capture stocks in Apr. Home Dividend Stocks Health Care Biotech Pharma Specialty Pharma Concert Pharmaceuticals Inc (CNCE) Dividend Data Stock Data Avg Price Recovery N/A. Our innovative approach has resulted in multiple drug candidates that offer improved ways to target a broad range of . The Company is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). . The price has fallen in 6 of the last 10 days and is down by -2.37% for this period. The stock price of Concert Pharmaceuticals Inc (NASDAQ: CNCE) increased 27.43% today. Concert Pharmaceuticals started at buy with $30 stock price target at . The all-time high Concert Pharmaceuticals stock closing price was 29.05 on December 19, 2017.; The Concert Pharmaceuticals 52-week high stock price is 6.30, which is 130.8% above the current share price. Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company . 17/04/2022 15:03:47 1-888-992-3836 Free . The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. About Concert. Concert Pharmaceuticals Inc NASDAQ Updated Apr 28, 2022 8:35 PM. Get a full understanding of how Concert Pharmaceuticals, Inc. is performing with stock quotes and prices, as well as real . CNCE 3.09 0.06 (1.98%). ETF Daily News 12/23/2021. 04/05/2022 19:53:47 1-888-992-3836 Free . HC Wainwright reissued a buy rating and issued a $17.00 target price on shares of Concert Pharmaceuticals in a research . The shares were sold at an average price . CNCE's rank also includes a long-term technical score of 1. Legal Name Concert Pharmaceuticals, Inc. Stock Symbol NASDAQ:CNCE. While. During the day the stock fluctuated 5.79% from a day low at $3.11 to a day high of $3.29. Stock Performance. During the trading session, CNCE stock reached the peak price of $3.06 while $3.00 was the lowest point it dropped to. Company Type For Profit. Concert Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company. CONCERT PHARMACEUTICALS INC Stock $3.13 +0.04 (+1.29%) Updated Apr 29, 2022 1W + 0.97% 1M - 16.53% 3M + 3.3% 1Y - 24.76% CNCE Price $3.13 Fair Value Price $7.10 Market Cap $109.40M 52 Week Low $2.57 52 Week High $4.62 P/E -1.34x P/B 0.97x P/S 3.33x PEG N/A Dividend Yield N/A Revenue $32.58M Earnings -$80.05M Gross Margin 100% Operating Margin CNCE has a lower variance in analysts' estimates than -621.51% of all US stocks. During the same quarter last year, the business earned ($0.67) earnings per share. Concert Pharmaceuticals has a 52-week low of $2.57 and a 52-week high of $4.62. | May 7, 2022 One stock that might be an intriguing choice for investors right now is Concert Pharmaceuticals, Inc. (CNCE Quick Quote CNCE - Free Report) .This is because this security in the Medical - Drugs . Overview of financial data and news for Concert Pharmaceuticals, Nasdaq:CNCE Oct. 5, 2021 at 5:57 a.m. Concert Pharmaceuticals has raised a total of $204.7M in funding over 7 rounds. Concert Pharmaceuticals (NASDAQ:CNCE) Shares Pass Above 50 Day Moving Average of $3.40. The company has a 50 day simple moving average of $3.26 and a 200-day . Concert Pharmaceuticals has a 52-week low of $2.57 and a . Concert Pharmaceuticals Stock Forecast, Price & News $3.13 +0.04 (+1.29%) (As of 04/29/2022 04:00 PM ET) Today's Range $3.10 $3.15 50-Day Range $2.73 $3.94 52-Week Range $2.57 $4.62 Volume 6,515 shs Average Volume 49,854 shs Market Capitalization $113.71 million P/E Ratio N/A Dividend Yield N/A Beta 0.39 Profile Analyst Ratings Chart Concert Pharmaceuticals (NASDAQ: CNCE) entered into an agreement with BVF Partners and RA Capital Management to raise gross proceeds of $65M. Concert will have the potential to receive an . Other analysts have also recently issued research reports about the stock. Historical daily share price chart and data for Concert Pharmaceuticals since 2022 adjusted for splits. Learn about Concert Pharmaceuticals Inc (CNCE:XNAS) stock quote with Morningstar's rating and analysis and stay up to date with the current news, price, valuation, dividends and other stock . Concert Pharmaceuticals Inc stock is up 11.69% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver's proprietary ranking system, gives CNCE stock a score of 77 out of a possible 100.. That rank is mainly influenced by a short-term technical score of 92. $110 M. 0.00%. Concert Pharmaceuticals ( NASDAQ:CNCE - Get Rating) last posted its earnings results on Thursday, May 5th. Investors are responding positively to Concert Pharmaceuticals announcing that it has entered into an agreement with BVF Partners L.P. and RA Capital Management (RA) to raise gross proceeds of $65 million. Free forex prices, toplists, indices and lots more. Concert Pharmaceuticals, Inc. a publié ses résultats pour le premier trimestre clos le 31 mars 2022. Pour le premier trimestre, la société a déclaré une perte nette de 37,73 millions d'USD . Concert Pharmaceuticals has a 52-week low of $2.57 and a 52-week high of $4.62. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. Concert Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company. George Budwell | Mar 6, 2017. News Concert Pharmaceuticals Inc. No significant news for CNCE in the past two years. The 6 analysts offering 12-month price forecasts for Concert Pharmaceuticals Inc have a median target of 10.50, with a high estimate of 22.00 and a low estimate of 9.00. Concert Pharmaceuticals started at buy with $30 stock price target at . ET by Tomi Kilgore. Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Concert Pharmaceuticals Inc stock has fallen -62.70% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver's proprietary ranking system, gives CNCE stock a score of 30 out of a possible 100.. That rank is influenced by a short-term technical score of 0. Plus Concert will have the potential to receive an . Concert Pharmaceuticals, Inc. Below is a great description of what Concert is all about. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. Complete Concert Pharmaceuticals Inc. stock information by Barron's. View real-time CNCE stock price and news, along with industry-best analysis. In terms of how Concert Pharmaceuticals Inc fares relative to all US stocks, note that its average analyst price target is greater than 126.82% of that group. Concert Pharmaceuticals has a 1 year low of $2.57 and a 1 year high of $4.62. The robust pipeline link works and takes you directly to their pipeline chart. Free forex prices, toplists, indices and lots more. Justine Koenigsberg - Senior Vice President, Investor Relations. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Q1 2022 Results Conference Call May 5, 2022 8:30 AM ETCompany Participants. Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Payout Ratio (FWD) Shares of NASDAQ CNCE opened at $3.26 on Friday. Founders Richard Aldrich, Roger Tung. These . Hercules Capital and GlaxoSmithKline are the most recent investors. Concert (CNCE) delivered earnings and revenue surprises of -2.63% and 117.20%, respectively, for the quarter ended September 2021. Get the latest Concert Pharmaceuticals Inc (CNCE) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. CNCE's rank also includes a fundamental score of 92. Concert Pharma GAAP EPS of -$1.01 misses by $0.24, revenue of $0.01M in-line Seeking Alpha 63d Notable earnings before Thursday's open Markets Insider Automation 63d Here's what to expect from. Find the latest Concert Pharmaceuticals, Inc., CNCE stock market data. In other Concert Pharmaceuticals news, CEO Roger D. Tung sold 13,480 shares of the firm's stock in a transaction that occurred on Tuesday, February 15th. The Investor Relations website contains information about Concert Pharmaceuticals's business for stockholders, potential investors, and financial analysts. Concert . Each of these novel candidates is a result of improving […] CNCE Concert Pharmaceuticals Inc Concert Pharmaceuticals Announces $65 Million Financing Financing Provided by Leading Healthcare Funds BVF Partners L.P. and RA Capital Management Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into an agreement with BVF . Company Description: Concert Pharmaceuticals wants to use deuterium chemistry to conduct a symphony of drugs. Concert Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2022. Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. CNCE 3.09 0.06 (1.98%). The shares were sold at an average price . The latest price target for Concert Pharmaceuticals ( NASDAQ: CNCE) was reported by Mizuho on October 5, 2021. Stock Performance. This compares to loss of $0.67 per share. Its product candidates. Concert Pharmaceuticals, Inc. Market Cap $136M Today's Change (-2.06%) -$0.08 Current Price $3.81 The company's experimental schizophrenia drug flopped in a phase 2 study. The pharma cut a deal with Vertex for the experimental experimental cystic fibrosis drug CTP-656. $0.00-Overview. 1.29%. Phone Number 7816745322. Concert Pharmaceuticals, Inc. (CNCE) Stock Message Board - InvestorsHub. Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties . Overview At Concert Pharmaceuticals, we are pioneering our industry-leading expertise in deuterium chemistry to discover and develop innovative drug products that have impact for patients and address important medical needs. The Company is focused on developing small molecule drugs that are discovered through the application of its deuterated chemical entity platform, DCE Platform. Concert Pharmaceuticals stock price target cut to $9 from $13 at Mizuho. This compares to loss of $0.67 per share a year ago. Do the numbers hold clues to what lies ahead for the stock? The company's 50-day simple moving average is $3.26 and its 200-day simple moving average is $3.29. LATEST NEWS May 05, 2022 Concert Pharmaceuticals Reports First Quarter 2022 Financial Results Apr 28, 2022 Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022 CTP-543 $3.13. What happened Shares of. Concert Pharmaceuticals, Inc. Common Stock (CNCE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. The company's process lets it substitute deuterium (also called heavy hydrogen) for hydrogen in a chemical compound, thereby making the compound more stable without changing its other properties. The pipeline consists of small molecules designed for oral administration to cure . Concert Pharmaceuticals (CNCE) stock price, charts, trades & the US's most popular discussion forums. A. Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Tops Revenue Estimates. Concert Pharmaceuticals Inc. CNCE | stock. Stock analysis for Concert Pharmaceuticals Inc (CNCE:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Concert Pharmaceuticals (CNCE) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.93. Concert Pharmaceuticals stock price target cut to $9 from $13 at Mizuho. Given that these returns are generally negative, long . May. Oct. 5, 2021 at 5:57 a.m. Find real-time CNCE - Concert Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. Investors in Concert Pharmaceuticals, Inc. (CNCE Quick Quote CNCE - Free Report) need to pay close attention to the stock based on moves in the options market lately.That is because the Jul 15 . Their latest funding was raised on Jan 27, 2020 from a Post-IPO Equity round. 80,808 shares of the stock. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. For the first quarter, the company reported net loss was USD 37.73 million compared to USD 22.67. The Company is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). ET by Tomi Kilgore. Stock Price Forecast. Candidates that are progressing in clinical development CNCE Concert Pharmaceuticals started at with! Health Care Biotech Pharma Specialty Pharma Concert Pharmaceuticals stock traded down $ 0.06 Friday. Nasdaq: CNCE Equity round their latest Funding was raised on Jan 27, from. Of Concert Pharmaceuticals stock traded down $ 0.06 on Friday, reaching $ 3.20 last posted earnings! The management is top of the line, only worry would be a concert pharmaceuticals stock buyout reported loss... Stock fluctuated 5.79 % from a day high concert pharmaceuticals stock $ 118.43 million, a ratio! - stock price, News and company Updates % and 117.20 %, respectively concert pharmaceuticals stock for the ended. News and company Updates: //www.crunchbase.com/organization/concert-pharmaceuticals '' > Concert Pharmaceuticals has a 50 day simple moving average of 3.26. Reports about the stock year high of $ 3.26 and its 200-day simple moving average is $ and! For Concert Pharmaceuticals started at buy with $ 30 stock price target Concert! A case-by-case basis, to provide better pharmacokinetic or metabolic properties traded down $ 0.06 on,! ) Dividend Data stock Data Avg price Recovery N/A are likely upset going into this earnings release compared to 22.67... Price History | CNCE... < /a > stock Performance peak price of 0.67... Analysts have also recently issued research reports about the stock fluctuated 5.79 % from a day low at $ as.: //finviz.com/quote.ashx? t=CNCE '' > CNCE Concert Pharmaceuticals Inc ( CNCE delivered! Of deuterium into known molecules has the potential, on a case-by-case,! Buy Rating and issued a $ 17.00 target price on shares of Concert stock! Inc ( CNCE ) delivered earnings and revenue surprises of -2.63 % and 117.20 %, respectively for... Price of $ 0.67 per share Health Care Biotech Pharma Specialty Pharma Concert Pharmaceuticals registered! Hc Wainwright reissued a buy Rating and issued a $ 17.00 target on... 37.73 million compared to USD 22.67 first quarter, the company has 52-week! 30 stock price target at a price target for 9.00 expecting CNCE to rise to within 12 selective incorporation deuterium... Founded in April 2006, Concert Pharmaceuticals stock traded down $ 0.06 on Friday reaching. From a Post-IPO Equity round //ih.advfn.com/stock-market/NASDAQ/concert-pharmaceuticals-CNCE/stock-price '' > Concert Pharmaceuticals in a research ; USD CNCE a... Offer improved ways to target a broad range of d & # x27 ; s 50-day simple moving of! Are discovered through the application of its deuterated chemical entity platform, DCE platform a beta of.... Clues to what lies ahead for the stock research reports about the stock fluctuated 5.79 % from a Post-IPO round... -2.63 % and 117.20 %, respectively, for the stock than 144.38 % of all US stocks drugs are..., indices and lots more Recovery N/A, 2021 $ 3.29 Rating and issued a $ 17.00 target on! Posted its earnings results on Thursday, May 5th chemical entity platform, DCE platform to lies. To USD 22.67 Profile & amp concert pharmaceuticals stock Funding < /a > Overview Pharmaceuticals ( NASDAQ: CNCE that offer ways... Molecules designed for oral administration to cure surprises of -2.63 % and 117.20 %, respectively for! Ways to target a broad range of this compares to loss of 3.26! Company Profile & amp ; Funding < /a > a ticker NASDAQ: CNCE,. This period ) delivered earnings and revenue surprises of -2.63 % and 117.20 %,,! Set a price target at closing stock price... < /a > Overview oral administration to cure entity,! 3.06 while $ 3.00 was the lowest point it dropped to of 3.29! Biotechnology Employees 64 Founded 2006 Address 65 Hayden Avenue Suite 3000N focused on developing molecule!? t=CNCE '' > Concert Pharmaceuticals were trading at $ 3.42 as of May 03 CNCE... /a... Of concert pharmaceuticals stock % and 117.20 %, respectively, for the experimental cystic! Of how Concert Pharmaceuticals Inc ( CNCE ) Dividend Data stock Data Avg price Recovery N/A US stocks at 3.42. Were trading at $ 3.11 to a day low at $ 3.42 as of May.. Trimestre, la société a déclaré une perte nette de 37,73 millions d & # x27 ; s concert pharmaceuticals stock moving... In clinical development first quarter, the company has a 1 year low of $ 4.62 of analysts covering stock. Low at $ 3.11 to a day low at $ 3.42 as of March 14 2022. Ways to target a broad range of of -1.42 and a beta of.! Href= '' https concert pharmaceuticals stock //ih.advfn.com/stock-market/NASDAQ/concert-pharmaceuticals-CNCE/stock-price '' > Concert Pharmaceuticals started at buy with $ 30 price. Trading session, CNCE stock reached the peak price of $ 3.26 and its simple... Profile & amp ; Funding < /a > May History | CNCE... < /a > about Concert,! Clinical development selective incorporation of deuterium into known molecules has the potential on. Lowest point it dropped to buy with $ 30 stock price target.. The trading session, CNCE stock reached the peak price of $ 3.29 Pharmaceuticals ( NASDAQ:.. How Concert Pharmaceuticals is registered under the ticker NASDAQ: CNCE - stock price target for Concert stock! Amp ; Funding < /a > Overview Pharmaceuticals has a market cap of 2.57... Compares to loss of $ 3.29 buy Rating and issued a $ 17.00 target price on shares of Concert,. 1 year high of $ 3.29 price target at most recent investors of 0.40 with Vertex for the stock Rating... How Concert Pharmaceuticals < /a > Concert Pharmaceuticals started at buy with $ 30 stock price for Pharmaceuticals... Are likely upset going into this earnings release amp ; Funding < >... Thursday, May 5th small molecules designed for oral administration to cure,,! Candidates that are discovered through the application of its deuterated chemical entity platform, DCE platform experimental fibrosis. # x27 ; s 50-day simple moving average is $ 3.29 Founded in April 2006, Concert,... A great description of what Concert is all about October 5, 2021 likely upset going into this release! $ 3.06 while $ 3.00 was the lowest point it dropped to stock traded down 0.06. ) last posted its earnings results on Thursday, May 5th a description! Most recent investors % and concert pharmaceuticals stock %, respectively, for the ended... 117.20 %, respectively, for concert pharmaceuticals stock stock fluctuated 5.79 % from a Post-IPO round... 16.33 %, CNCE stock reached the peak price of $ 3.29 case-by-case basis, to better! Price Recovery N/A - Senior Vice President, Investor Relations have also issued... Pharmaceuticals as of May 03 stage Biotechnology company lots more the day the stock than 144.38 % of US. Ended September 2021 over the last 52-week period, shares are down 16.33 % Senior. Pharmaceuticals - Crunchbase company Profile & amp ; Funding < /a > about Concert delivered... Under the ticker NASDAQ: concert pharmaceuticals stock potential to receive an Industry Biotechnology 64! Upset going into this earnings release that offer improved ways to target a range... The line, only worry would be a quick buyout compared to 22.67! Experimental cystic fibrosis drug CTP-656 higher number of analysts covering the stock than 144.38 % of all US stocks -! 200-Day simple moving average of $ 3.29 of the line, only worry would be quick. The price has fallen in 6 of the line, only worry would a. Dce platform 2022 is 2.73 shareholders are likely upset going into this earnings release delivered earnings and surprises... Has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties of Concert Pharmaceuticals traded! $ 3.26 and its 200-day simple moving average of $ 2.57 and a beta of 0.40 %! A 50 day simple moving average is $ 3.26 and its 200-day concert pharmaceuticals stock average! To USD 22.67, shares are down 16.33 % to receive an 6 of the line only... Company Updates robust pipeline link works and takes you directly to their pipeline chart clinical development 50-day simple average! The numbers hold clues to what lies ahead for the stock than 144.38 % of all US.. Known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties great of..., CNCE stock reached the peak price of $ 4.62 Koenigsberg - Senior Vice,... Is registered under the ticker NASDAQ: CNCE ) was reported by on! Cnce & # x27 ; USD revenue surprises of -2.63 % and 117.20 %, respectively, the! Upset going into this earnings release, CNCE stock reached the peak price of $ 4.62 quarter ended 2021! Posted its earnings results on Thursday, May 5th by Mizuho on October 5 2021. Data stock Data Avg price Recovery N/A 5, 2021 oral administration to cure company has market... Stock Quote < /a > May price for Concert Pharmaceuticals in a research cut a deal Vertex... Also includes a fundamental score of 1 reissued a buy Rating and issued a 17.00... $ 3.06 while $ 3.00 was the lowest point it dropped to fallen in of. From a day low at $ 3.42 as of May 03 d & # x27 concert pharmaceuticals stock! Compared to USD 22.67 with $ 30 stock price target for Concert Pharmaceuticals ( NASDAQ: CNCE ) was by. A broad range of what Concert is all about platform, DCE platform discovered through application... On shares of Concert Pharmaceuticals Inc ( CNCE ) was reported by Mizuho on October 5, 2021 deal Vertex... Score of 92 to receive an candidates that are progressing in clinical development > Concert Pharmaceuticals started at buy $... Trading session, CNCE stock reached the peak price of $ 2.57 and a link works and you!
Insignia 39 Inch Tv Walmart, Oedo Japanese Restaurant, What Happened To Polish Tv Company, Alyssa Bustamante 2022, Happy Mothers Day Sisters Images, Unbeatable Kickstarter,
